Abstract
SAC / VAL is considered a treatment option for patients with heart failure with reduced ejection fraction (≤ 35%), high levels of type B natriuretic peptide (PNB) or aminothermal fragment of type B natriutetic peptide (NT-proPNB). ) and that they continue to be symptomatic (NYHA class II-III) despite stable treatment with the maximum tolerated doses of an IECA or an ARA-II together, except with contraindication, with a beta-blocker and an aldosterone antagonist
Keywords
Chronic heart failure; Adults; Sacubitril; Valsartan
Bibliographic citation
Informe d'utilització de sacubitril/valsartan a Catalunya: informe d'utilització de medicaments. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4744This item appears in following collections
The following license files are associated with this item: